The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: Ovarian cancer (OC) subset—A study of the Princess Margaret, Mayo, Southeast phase II, and California Cancer (CCCP) N01 Consortia NCI#8233.
R. Morgan
No relevant relationships to disclose
A. M. Oza
No relevant relationships to disclose
R. Qin
No relevant relationships to disclose
K. M. Laumann
No relevant relationships to disclose
H. Mackay
No relevant relationships to disclose
E. L. Strevel
No relevant relationships to disclose
S. Welch
No relevant relationships to disclose
D. Sullivan
No relevant relationships to disclose
R. M. Wenham
No relevant relationships to disclose
H. X. Chen
No relevant relationships to disclose
L. A. Doyle
No relevant relationships to disclose
D. R. Gandara
No relevant relationships to disclose
C. Erlichman
No relevant relationships to disclose